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polymorphismAbstract The hypoxia inducible factor 1 alpha (HIF1a) is a key regulator of tumour cell
response to hypoxia, orchestrating mechanisms known to be involved in cancer aggressiveness
and metastatic behaviour. In this study we sought to evaluate the association of a functional
genetic polymorphism in HIF1A with overall and metastatic prostate cancer (PCa) risk and
with response to androgen deprivation therapy (ADT).
The HIF1A +1772 C>T (rs11549465) polymorphism was genotyped, using DNA isolated
from peripheral blood, in 1490 male subjects (754 with prostate cancer and 736 controls can-
cer-free) through Real-Time PCR. A nested group of cancer patients who were eligible for
androgen deprivation therapy was followed up. Univariate and multivariate models were used
to analyse the response to hormonal treatment and the risk for developing distant metastasis.
Age-adjusted odds ratios were calculated to evaluate prostate cancer risk.
Our results showed that patients under ADT carrying the HIF1A +1772 T-allele have
increased risk for developing distant metastasis (OR, 2.0; 95%CI, 1.1–3.9) and an independent
6-fold increased risk for resistance to ADT after multivariate analysis (OR, 6.0; 95%CI, 2.2–
16.8). This polymorphism was not associated with increased risk for being diagnosed with
prostate cancer (OR, 0.9; 95%CI, 0.7–1.2).Porto,
360 A. Fraga et al. / European Journal of Cancer 50 (2014) 359–365The HIF1A +1772 genetic polymorphism predicts a more aggressive prostate cancer behav-
iour, supporting the involvement of HIF1a in prostate cancer biological progression and
ADT resistance. Molecular proﬁles using hypoxia markers may help predict clinically relevant
prostate cancer and response to ADT.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Prostate cancer (PCa) remains a major public health
concern because it is the most common malignant neo-
plasia and the second leading cause of cancer death in
men [1].
Clinically, it is a heterogeneous disease, with aggres-
siveness risk diﬀering greatly among individuals despite
similar clinical and pathological characteristics. Cur-
rently, only incipient but scarce markers help to predict
whether PCa will be an aggressive, fast growing disease
or an indolent slow growing type of cancer [2]. There-
fore, new strategies to help clinicians distinguish
between lethal and indolent prostate cancer are needed.
Recent ﬁndings indicate that genetic variants may pre-
dispose to more aggressive prostate cancer [3–5], which
is supported by epidemiological studies that propose
genetic background inﬂuences cancer prognosis [6–8].
Recent genome-wide association studies (GWAS)
revealed numerous genetic variants associated with
prostate cancer risk, although only little discriminatory
ability was shown for fatal forms of the disease [9].
Intratumoural hypoxia is a hallmark of solid neopla-
sias. It is well established that hypoxic tumoural micro-
environment initiates multiple cellular responses,
ultimately resulting in cancer progression [10,11]. The
hypoxia inducible factor 1 alpha (HIF1a) is a transcrip-
tion factor coded by the HIF1A gene that regulates cel-
lular response to hypoxia [12,13], inducing cancer
progression through activation of many genes involved
in regulatory cancer biology (angiogenesis, cell metabo-
lism, cell survival, and epithelial-to-mesenchymal transi-
tion) [14]. The HIF1A gene harbours several SNPs,
including a C-to-T substitution at locus +1772 that
result in aminoacid modiﬁcation (proline by serine). Pre-
vious in vitro studies showed higher transcriptional
activity of the variant allele under both normoxic and
hypoxic conditions [12,14], whereas additional research
associated this SNP with increased tumour microvessel
density [12,14,15].
Recent studies yielded conﬂicting results regarding the
involvement of HIF1A +1772 C>T genetic polymor-
phism in cancer, albeit a signiﬁcant positive association
remained after meta-analysis in Caucasian women spe-
ciﬁc cancers [16,17]. In prostate cancer, the few studies
were conducted in distinct ethnic populations and clinico-
pathological characteristics leading to conﬂicting
results [16,18,19]. Furthermore, the association ofHIF1A
+1772 C>T SNP with prostate cancer progression,metastasis and refractoriness to androgen deprivation
therapy (ADT) merits further evaluation in larger series
of patients. In the present study we sought to analyse
the association of the functional SNP +1772 C>T in
HIF1A with PCa using prostatic biopsy-proven controls,
and to predict the response to treatment in men receiving
ADT.
2. Patients and methods
2.1. Patients
Subjects with histological conﬁrmation, whether on
biopsy or surgical specimen, of prostate cancer
(n = 754) or absence of malignancy (n = 736) were
included in a case-control study. Patients were recruited
from ﬁve Hospitals in Portugal between 1990 and 2009:
Portuguese Institute of Oncology – Porto Centre, S.
Joa˜o Hospital, Porto Military Hospital, Porto Hospital
Centre, and Central Lisbon Hospital Centre. The study
was approved by hospital’s research ethics committees
and consent obtained from participants.
The non-PCa control group comprises men referred
for prostate biopsy (8–13 cores) on the basis of abnor-
mal digital rectal examination and/or single baseline
PSA levels over 2.5 ng/ml, but with normal or benign
prostatic histology. Subjects without malignancy at
biopsy (BPH or chronic prostatitis) were considered
controls since (1) diagnosis was contemporary, (2) were
age matched with elderly cancer patients, (3) all were
submitted to digital rectal examination, PSA estimate
and prostatic biopsy, making remote the possibility of
crossover, (4) most men have benign diseases of the
prostate by the 7th–8th decades of life, making it normal
in men of that age, (5) bias would be expectable if only
men without prostatic disease were eligible, because of
the much younger range of ages. Patients with high-
grade prostatic intraepithelial neoplasia or a biopsy sus-
picious of cancer were excluded.
A nested sample of subjects from the group of PCa
patients (those eligible for androgen deprivation ther-
apy, ADT, (n = 429) was followed up for several years.
These patients were submitted to orchiectomy or lutein-
ising hormone releasing hormone agonist (LHRHa)
(with or without anti-androgen) immediately after
diagnosis or after relapsing from surgery/radiotherapy.
Resistance to ADT was deﬁned as the time from ADT
initiation to two consecutive rises of PSA greater than
the PSA nadir or progression of bone lesions [20,21].
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routinely in use and determined by international,
namely European, guidelines [20,22]. Information was
collected through chart review.2.2. Genotyping
A venous blood sample (6 ml) was obtained by fore-
arm venipuncture and the white cell fraction used to
extract DNA (QIAmp DNA Blood Mini Kit, Qiagen).
Blood samples for genetic analysis were collected inde-
pendent of treatment initiation. The HIF1A +1772
C>T (rs11549465) genetic polymorphism was genotyped
by Real-Time PCR using a pre-designed validated Taq-
man assay (Applied Biosystems). Procedures imple-
mented for quality control included double sampling
in about 5% of samples and the use of negative controls
in every run.2.3. Statistical analysis
The Kolmogorov–Smirnov test was used to assess
departure from normality of continuous variables, while
medians and interquartile ranges were used as descrip-
tive statistics. The Mean diﬀerences between groups
for data not normally distributed was compared by
Mann–Whitney or Kruskal–Wallis tests. The departure
from Hardy-Weinberg equilibrium for HIF1A +1772
C>T polymorphism in the non-prostate cancer group
was tested by Pearson’s chi-square.
Unconditional logistic regression was used to esti-
mate age-adjusted odds ratios (aORs) and 95% conﬁ-
dence intervals (95%CIs) for the associations between
the polymorphism and development of prostate cancer
based on additive, recessive and dominant genetic mod-
els (additive, CC versus Ct versus tt, and based on the
minor allele: dominant, CC versus Ct + tt; recessive,
CC + Ct versus tt). We examined the association of
HIF1A +1772 C>T genetic polymorphism with overall
prostate cancer and restricted to high-grade prostate
cancer (combined Gleason scoreP7) in comparison
with controls non-cancers.
Serum PSA at diagnosis was stratiﬁed according to a
20 ng/ml cutoﬀ, the combined Gleason score was strati-
ﬁed into two groups (<7 versus P7), whereas clinical
stage was further stratiﬁed as localised (T1–T2) or
advanced (deﬁned as a tumour invading and extending
beyond the prostate capsule and/or extending into adja-
cent tissue, involving regional lymph nodes and/or dis-
tant metastatic sites). The time-to-resistance to ADT
was calculated as the interval (in months) since the
beginning of ADT until the date of resistance to ADT
or last visit.
Empirical analyses were conducted to determine
covariates for multivariate models. For time-to-event
analyses, age-adjusted Cox regression models were usedto assess risk of ADT resistance, whereas age-adjusted
logistic regression models were used to evaluate the risk
for metastasis. Then, multivariate analysis included rel-
evant clinical variables from empirical evaluation and
genetic models. A multivariate Cox proportional haz-
ards model was derived to identify the independent pre-
dictive risks for biochemical progression under
hormonal castration, while a multivariate logistic regres-
sion model was performed to evaluate clinical and
genetic predictive factors for prostate cancer metastasis.
Statistical analyses were done using STATA version
10.0 (StataCorp, College Station, Texas).3. Results
One-thousand four hundred ninety individuals were
included in this study, 736 cancer-free controls and
754 with a positive biopsy for prostate cancer (median
age, 66.8 and 68.0 years old, respectively, p = 0.001).
Biopsy ﬁndings in the control cancer-free group revealed
normal histology (10.9%), benign prostatic hyperplasia
(33.4%), chronic prostatitis (55.2%) and atrophy
(0.5%). As expected, PCa patients presented signiﬁcantly
higher serum PSA levels at diagnosis (p < 0.0001).
HIF1A +1772 (rs11549465) genotype distribution by
group and risk analysis is shown in Table 1. Both addi-
tive and dominant genetic models were not associated
with prostate cancer risk or high grade disease. The dis-
tribution of HIF1A +1772 C>T genotypes among the
non-cancer control subjects were in agreement with
Wardy–Weinberg equilibrium (p = 0.988). Furthermore,
we found that this SNP was not associated to earlier
onset of disease, using Kaplan–Meier plots and func-
tions (data not shown).
In the group of prostate cancer patients, analyses of
the association between HIF1A +1772 genetic variants
and patient’s clinicopathological characteristics showed
over-representation of T-allele in the group of patients
not treated with deﬁnitive therapy (p = 0.05) and who
developed metastasis at any time during the course of
malignant disease (Table 2).
From the group of 754 patients with prostate cancer,
429 were eligible for androgen deprivation therapy,
either due to advanced disease at diagnosis or due to dis-
ease progression. The clinicopathological characteristics
of this nested group are shown in Table 3. From the
group of patients on ADT, 194 (45.2%) developed resis-
tance to hormonal therapy. The median (95%CI) follow-
up time was 91.8 (79.8–103.7) months.
Univariate age-adjusted empirical time-to-ADT
resistance analysis on clinical covariates showed that
Gleason gradeP7 (HR, 2.8; 95%CI, 2.0–4.1), advanced
clinical stage (HR, 3.7; 95%CI, 2.5–5.3), deﬁnitive treat-
ment (HR, 0.6; 95%CI, 0.4–0.8), PSAP 20 ng/ml (HR,
1.9; 95%CI, 1.5–2.6) and presence of metastasis at
ADT initiation (HR, 2.9; 95%CI, 2.1–3.9) were all
Table 1
HIF1A +1772 genotype distribution and risk for prostate cancer.
Prostate cancer
Control All High-grade (Gleason P7)
HIF1A genotypes N N aOR (95%CI) N aOR (95%CI)
Additive model
CC 566 579 Referent 333 Referent
CT 156 164 1.0 (0.8–1.3) 83 0.9 (0.7–1.2)
TT 14 11 0.9 (0.4–2.1) 7 1.0 (0.4–2.5)
Dominant model
CC 566 579 Referent 333 Referent
T carriers 170 175 1.0 (0.8–1.3) 90 0.9 (0.7–1.2)
aOR(95%CI), age-adjusted odds ratios and the respective 95% conﬁdence intervals.
Table 2
Genotype distribution in PCa subjects (n = 754) according to clinicopathological characteristics.
HIF1A +1772 C>T genotypes
CC (n = 579) CT (n = 164) TT (n = 11) p
Deﬁnitive therapy
No 228 (75.0) 69 (22.7) 7 (2.3)
Yes 281 (78.5) 76 (21.2) 1 (0.3) 0.05*
Clinical stage
Localised 262 (78.9) 67 (20.2) 3 (0.9)
Advanced 222 (76.0) 66 (22.6) 4 (1.4) 0.639*
Gleason score
<7 177 (75.0) 56 (23.7) 3 (1.3)
P7 333 (78.7) 83 (19.6) 7 (1.7) 0.443*
Tumour percenta 17.0 (6.0–40.0) 20.0 (5.0–38.5) 65.0 (50.0–80.0) 0.185**
Data are presented as number of cases and respective percentage.
a Median (interquartile range).
* Chi-square test.
** Kruskal–Wallis test. Columns do not sum up because of missing data.
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associations between HIF1A +1772 C>T genotypes
and the time-to-event age-adjusted univariate and multi-
variate analyses are shown in Table 4. Although we have
not found association of HIF1A +1772 C>T polymor-
phism with resistance to ADT on univariate analysis,
in the recessive model the T homozygous genotype
was associated with a 6-fold higher risk for developing
resistance to ADT, after adjustment for relevant clinico-
pathological variables (Gleason grade, clinical stage,
PSAP 20 ng/ml, deﬁnitive therapy and existence of
metastases at the time of hormonal castration initiation)
(Table 4). The risk of developing metastasis at any time
during the course of disease in patients under ADT was
signiﬁcantly higher for T-allele carriers, still after adjust-
ment for other clinical covariates (Gleason grade, clini-
cal stage and PSAP 20 ng/ml) (Table 5).
4. Discussion
Hypoxia is a frequent event during prostate cancer
progression, while the hypoxia-responsive gene HIF1Acodes for a key transcription factor that has been pro-
posed as a modulator of PCa initiation and progression
[23–25]. We analysed a functional SNP (+1772 C>T) in
the HIF1A gene in prostate cancer patients and controls
and found lack of association, although a relatively
large population with approximately 1500 men was ana-
lysed. Concordantly, two large case-control studies from
the United States of America and China also observed
no risk for having PCa in carriers of this polymorphism
[19,26], even though opposite results have been also
reported [16,27]. The C-by-T substitution in the +1772
locus at the oxygen-dependent domain of the HIF1A
gene results in a proline-to-serine substitution and was
shown to stabilise HIF1A and enhance its activity as a
transcription factor in both normoxia and hypoxia
[12,28]. In agreement, albeit we hypothesised those car-
riers of T allele were more susceptible to have cancer,
our data, together with other, suggest no inﬂuence in
earlier stages of prostate cancer development. As PCa
natural history usually reveals slow growing indolent
tumours, the initial steps of carcinogenesis are not likely
to be relevant sources of hypoxia, thereby inducing the
Table 3
Clinicopathological characteristics features of the group of patients
under that received ADT (n = 429).
n (%)
Age at diagnosis, yrs
Median (IQR) 70.0 (64.9–75.4)
PSA at diagnosis, ng/ml
Median (IQR) 19.0 (8.9–51.6)
Gleason score
<7 128 (32.2)
P7 269 (67.8)
Clinical stage
Localised 156 (38.7)
Advanced 247 (61.3)
Metastasis at ADT initiation
No 286 (75.9)
Yes 91 (24.1)
Deﬁnitive therapy
No 299 (69.7)
RP/RT 130 (30.3)
ADT pharmacological group
aLHRH alone 91 (21.2)
aLHRH + antiandrogen 338 (78.8)
ADT, androgen deprivation therapy; aLHRH, luteinising hormone
releasing hormone agonist; RP/RT, radical prostatectomy/radiother-
apy; IQR, interquartile range.
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previous report found that HIF1A +1772 C>T geno-
types were not correlated with HIF1a and VEGF
expression in localised prostatic tumours [16]. However,
HIF1a overexpression has been reported in cancer pre-
cursor lesions, high grade prostate intraepithelial neo-
plasia, and early stage PCa, compared with normal
prostate epithelium [24].
Previous studies have shown overexpression of
HIF1a in many tumours with advanced grade, implying
HIF1a as an independent prognostic factor in cancer
[15]. In addition, increasing evidence suggests thatTable 4
Association of HIF1A +1772 C>T polymorphism with resistance to ADT
Resistance to AD
Univariate
HIF1A +1772 C>T LR HR (95%CI)
Additive model 2.24
CC Referent
CT 0.8 (0.6–1.2)
TT 1.8 (0.7–4.6)
Dominant model 2.70
CC Referent
T carriers 0.9 (0.6–1.2)
Recessive model 3.86
C carriers Referent
TT 1.9 (0.8–4.8)
LR, likelihood ratio. ADT, androgen deprivation therapy. HR, hazard rat
* Cox regression using as covariates: Gleason grade, clinical stage, PSAP
hormonal castration initiation.genetic markers may be independent predictors of out-
come in PCa with various SNPs predicting decreased
progression-free and overall survival [3–6]. Data pre-
sented here show that the homozygous T genotype T-
allele of HIF1A +1772 C>T is associated with increased
relapsing after ADT, whereas the T allele is prone to
higher risk for having distant metastasis, still after
adjustment for empirical covariates (adjusted by Glea-
son grade, clinical stage and PSAP 20 ng/ml for the
risk of metastasis; and by Gleason grade, clinical stage,
PSAP 20 ng/ml, deﬁnitive therapy and existence of
metastases at the time of hormonal castration initiation
for the risk of disease recurrence after ADT). While the
recessive model (TT versus CT/CC) was signiﬁcantly
associated with resistance to ADT, the dominant (TT/
CT versus CC) and additive models were signiﬁcant
for metastasis development under ADT. A recently pub-
lished meta-analysis suggests that both the T allele and
TT genotype were signiﬁcantly associated with increased
cancer risk [17]. Experimental data also support a func-
tional role for the C-by-T substitution at the allele and
homozygous genotype level [12,28,29]. We found that
additivity was better ﬁtted for metastasis but not to
ADT resistance, even though the low number of patients
carrying the TT genotype in metastasis analyses yielded
a very wide CI, hence deserving careful interpretation.
Our ﬁndings in a large cohort of patients that
received ADT, support a role for HIF1a in the patho-
physiology of castration resistance and the HIF1A
+1772 C>T polymorphism as a potential pharmacoge-
nomic predictor of the response to ADT. Concordantly,
a recent study demonstrated that HIF1a expression con-
tributed both to metastasis and chemo-resistance of cas-
tration resistant prostate cancer [30]. A study comparing
HIF1A +1772 C>T genotypes between castration-resis-
tant PCa and non-cancer men showed that the T-allele
was overrepresented in the cancer group, although it
was not associated with survival [18]. Noteworthy, this
report presents data from 196 castration-resistant.
T
Multivariate*
p HR (95%CI) p
Referent
0.288 1.0 (0.7–1.5) 0.918
0.183 6.1 (2.2–17.0) 0.001
0.460 1.1 (0.8–1.7) 0.536
Referent
0.149 6.0 (2.2–16.8) 0.001
io; 95%CI, 95% conﬁdence interval.
20 ng/ml, deﬁnitive therapy and existence of metastases at the time of
Table 5
Risk for metastasis in patients receiving androgen deprivation therapy
Univariate analysis* Multivariate analysis**
HIF1A +1772 C>T N OR (95%CI) p N OR (95%CI) p
Additive model 380 323
CC Referent Referent
CT 1.7 (1.0–2.7) 1.9 (1.0–3.6)
TT 3.5 (0.6–19.4) 0.055a 14.9 (1.0–223.1) 0.031a
Dominant model
CC Referent Referent
T carriers 380 1.7 (1.1–2.8) 0.023 323 2.0 (1.1–3.9) 0.027
Recessive model 380 323
C carriers Referent Referent
TT 3.1 (0.6–17.1) 0.199 12.9 (0.9–190.1) 0.063
a p for trend. OR (95%CI), odds ratio with 95% conﬁdence interval.
* Age-adjusted ORs.
** Multivariate logistic regression analysis using Gleason grade, clinical stage and PSA with cut-oﬀ 20 ng/ml as covariates.
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observed a somatic rare mutation at the same locus in
1/15 androgen-independent prostate tumours, whereas
functional studies demonstrated in androgen-indepen-
dent prostate cancer cells that the T-allele is associated
with increased transcriptional activity and protein
expression [28]. Therefore, we hypothesise that carrying
the T-allele, which stabilises HIF1a protein and upregu-
lates the HIF1A1 gene expression, may oﬀer a selective
advantage to androgen-independent tumour cells
through the upregulation of several genes involved in
metastasis, angiogenesis, epithelial-to-mesenchymal
transition or in other cancer-associated mechanisms
[10,23,31–33]. The SNP in HIF1A at locus +1772 repre-
sents a germline variant, suggesting a cumulative impact
of higher HIF1a expression since birth. However, we
hypothesise that HIF1A+1772 functional SNP repercus-
sion when combined with hypoxic environmental events
or with other genetic risk factors is triggered to higher
extent in response to hypoxia-inductive treatments such
as ADT. When conﬁrmed in larger and independent
samples, additional therapeutic schemes (such as
CYP17A1 inhibitors or chemotherapy) could be oﬀered
to carriers of the poor responder TT genotype as alter-
native to ADT. These patients could also be enrolled
in clinical trials with drugs that target HIF1a function
(e.g. tasquinimod and other agents that target HIF1a
or its downstream products) [34–37].
Present ﬁndings should be further extended and rep-
licated by future studies focusing on genetic polymor-
phisms as predictors of treatment response to allow
tailored therapy in PCa patients. Using this focused can-
didate gene approach to evaluate the HIF1A +1772
C>T SNP gives us an incomplete analysis of hypoxia
mechanism. Other hypoxia-related SNPs were not
included in this study. However, our study has several
strengths such as the selection of the candidate gene
based on biological evidence of functional importance;
statistical analyses accounted for relevant clinical and
pathological factors. In this study all men (includingthe controls) were screened for prostate cancer based
on both PSA level and digital rectal exam during the
recruitment period and diagnosis was determined by
standard biopsy or surgical sample, thus making out-
come misclassiﬁcation unlikely.
Our ﬁndings suggest that the HIF1A +1772 C>T
might be a useful marker of aggressive PCa, particularly
a predictor of the response to ADT, thus a plausible
candidate to include in a panel of risk prediction SNPs
in combination with clinical and pathologic features.5. Conﬂict of interest statement
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